Novel bispecific antibodies show promise against evolving SARS-CoV-2 variants

FHS
May 9, 2024
4:38 am

Researchers developed bispecific antibodies targeting both the N-terminal and receptor binding domains of SARS-CoV-2, demonstrating significant neutralization across various Omicron variants, suggesting potential for new COVID-19 treatments.

UVA researchers discover key driver of chronic inflammation that accelerates aging

University of Virginia School of Medicine researchers have discovered a key driver of chronic inflammation that accelerates aging.

July 25, 2023

FDA approves Italfarmaco’s drug Duvyzat for Duchenne muscular dystrophy

The FDA approved the first nonsteroidal drug to treat all genetic variants of Duchenne muscular dystrophy, clearing drugmaker Italfarmaco’s oral treatment for patients age 6

March 22, 2024

Research develop a revolutionary toolkit to combat digital exclusion

Researchers create a composite indicator for digital exclusion and a related toolbox.

August 7, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.